BBNX CCO Mark Hopman exercises options and executes Rule 10b5-1 sale at $16.61 avg

Rhea-AI Filing Summary

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported coordinated transactions on 08/19/2025 under a Rule 10b5-1 plan adopted May 13, 2025. He exercised an employee stock option with a $5.10 exercise price to acquire 16,158 shares. The same day he sold 16,158 shares pursuant to the 10b5-1 plan at a weighted average sale price of $16.6095, with reported price range of $16.26 to $17.1719. The filing shows beneficial ownership counts of 50,290 shares following the acquisition line and 34,132 shares following the reported sale; the derivative table reports 16,158 option shares underlying and 67,084 total shares beneficially owned following the derivative transaction line. The form is signed by an attorney-in-fact on 08/20/2025.

Positive

• Transaction transparency: The filing discloses exercise, sale, weighted average sale price and price range.
• 10b5-1 plan adoption disclosed: The sale was executed pursuant to a Rule 10b5-1 plan adopted May 13, 2025.
• Complete option detail: Exercise price ($5.10), number of options/shares (16,158) and vesting schedule language are provided.

Negative

• Reduction in direct holdings: Beneficial ownership reported decreases from 50,290 shares to 34,132 shares after the sale.
• Potential dilution disclosure required: The exercise of options increases outstanding shares; the filing shows option shares underlying but does not quantify company-wide dilution impact.

Insights

Securities Analyst

TL;DR Insider exercised options then sold an equal number of shares under a 10b5-1 plan; transaction appears routine and executed at a material premium to exercise price.

The reporting shows an option exercise at a $5.10 strike converting to 16,158 common shares and an immediate sale of those 16,158 shares under a Rule 10b5-1 plan at a weighted average of $16.6095. The spread between exercise price and sale price indicates a realized difference per share, but this filing is a disclosure of insider activity rather than an operational update. The 10b5-1 plan adoption date (May 13, 2025) and the provided sale price range are explicitly disclosed, enabling verification of transaction timing and pricing.

Corporate Governance Expert

TL;DR Disclosure is standard and compliant: exercise plus Rule 10b5-1 sale is properly documented and signed by an attorney-in-fact.

The Form 4 identifies the reporting person, role (Chief Commercial Officer), transaction dates, pricing details and the 10b5-1 plan adoption date. The explanatory footnote clarifies price range and offers supplemental pricing details on request. Signature by an attorney-in-fact on 08/20/2025 is included, which satisfies filing formalities. No amendments or additional restrictive terms are provided in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		M		16,158	A	$5.1	50,290	D
Common Stock	08/19/2025		S(1)		16,158	D	$16.6095(2)	34,132	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.1	08/19/2025		M			16,158	(3)	07/26/2033	Common Stock	16,158	$0	67,084	D

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.

2. The weighted average sale price for the transaction reported was $16.6095 and the range of prices were between $16.26 and $17.1719. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.

	/s/ Stephen Feider, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Mark Hopman (BBNX) report on 08/19/2025?

He exercised an employee stock option for 16,158 shares at a $5.10 exercise price and sold 16,158 shares under a Rule 10b5-1 plan at a weighted average sale price of $16.6095.

Was the sale executed under a pre-established plan for Mark Hopman (BBNX)?

Yes. The filing states the shares sold were pursuant to a Rule 10b5-1 plan adopted on May 13, 2025.

What price range was disclosed for the shares sold by the reporting person?

The filing discloses a sale price range of $16.26 to $17.1719 and a weighted average sale price of $16.6095.

How did these transactions change the reporting person’s beneficial ownership?

The form lists 50,290 shares following the acquisition line and 34,132 shares following the sale line; the derivative table reports 16,158 option shares and 67,084 total shares in that section.

Who signed the Form 4 and when?

The form is signed by /s/ Stephen Feider, Attorney-in-Fact with a signature date of 08/20/2025.